Tammy Woodard
Obstetrics & Gynecology · Smithfield, NCNPI 1700987427
Payments from drug & device makers
Across 221 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$582
- Mayne Pharma Commercial LLC$503
- Astellas Pharma US Inc$308
- Daiichi Sankyo Inc.$268
- Novo Nordisk$194
- Pfizer$180
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,892100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $582 |
| Mayne Pharma Commercial LLC | 29 | $503 |
| Astellas Pharma US Inc | 18 | $308 |
| Daiichi Sankyo Inc. | 14 | $268 |
| Novo Nordisk | 13 | $194 |
| Pfizer | 10 | $180 |
| Biogen | 8 | $161 |
| Exeltis, USA Inc. | 9 | $153 |
| Shield Therapeutics Inc | 3 | $151 |
| Agile Therapeutics, Inc. | 8 | $136 |
| Evofem Biosciences, Inc. | 7 | $109 |
| Therapeuticsmd, Inc. | 6 | $100 |
| Organon | 8 | $97 |
| Lilly USA, LLC | 5 | $88 |
| Avion Pharmaceuticals | 6 | $86 |
| Sage Therapeutics, LLC | 4 | $74 |
| Currax Pharmaceuticals LLC | 5 | $73 |
| Coopersurgical, Inc. | 3 | $58 |
| Myovant Sciences Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Endo Pharmaceuticals Inc. | 3 | $49 |
| LSI Solutions Inc | 1 | $41 |
| Merck | 2 | $33 |
| Lupin Inc. | 2 | $32 |
| Medtronic | 1 | $29 |
| Dexcom, Inc. | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Amgen | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Avanos Medical | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Mylan Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Aspira Women's Health Inc | 1 | $16 |
| Millicent US Inc | 1 | $13 |
| Vivus LLC | 1 | $13 |
How this compares
$3,906 in reported general payments places this provider in the 85th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
See all obstetrics & gynecology providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 33 | $2,169 |
| Estradiol (Twice Weekly)Estradiol | 17 | $1,718 |
| MyrbetriqMirabegron | 16 | $1,200 |
| Nystatin | 23 | $317 |
| Clobetasol Propionate | 11 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $308 | $1,20016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
Other obstetrics & gynecology in Smithfield
- Laura McKainWilmington$2.6M
- Robert ParkerWinston-Salem$2.1M
- Allison PuechlCharlotte$1.6M
- Jeffrey MichelsonNew Bern$1.2M
- Robert LittletonRaleigh$976K
- Donald HornerCharlotte$907K
- Rebecca Dunsmoor SuMorrisville$837K
- Ann CollinsRaleigh$701K
- Kathryn PattenHendersonville$550K
- Mohamad Mehdi ParvaElizabeth City$538K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.